Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 21.9% in December

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 265,860 shares, a drop of 21.9% from the November 30th total of 340,426 shares. Approximately 1.7% of the company’s shares are short sold. Based on an average daily volume of 166,993 shares, the short-interest ratio is currently 1.6 days. Based on an average daily volume of 166,993 shares, the short-interest ratio is currently 1.6 days. Approximately 1.7% of the company’s shares are short sold.

Institutional Investors Weigh In On Allarity Therapeutics

A number of large investors have recently modified their holdings of ALLR. Citadel Advisors LLC acquired a new stake in shares of Allarity Therapeutics in the 3rd quarter valued at $149,000. Private Advisor Group LLC acquired a new stake in Allarity Therapeutics in the third quarter valued at $441,000. Jane Street Group LLC acquired a new stake in Allarity Therapeutics in the second quarter valued at $27,000. XTX Topco Ltd purchased a new stake in Allarity Therapeutics during the 2nd quarter worth about $51,000. Finally, Geode Capital Management LLC boosted its position in shares of Allarity Therapeutics by 49.3% during the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after acquiring an additional 16,729 shares in the last quarter. 11.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ALLR. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, October 8th. Ascendiant Capital Markets boosted their price objective on Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Wall Street Zen raised Allarity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $9.50.

Allarity Therapeutics Price Performance

ALLR opened at $1.05 on Tuesday. The business has a fifty day moving average price of $1.19 and a 200 day moving average price of $1.24. Allarity Therapeutics has a 12 month low of $0.61 and a 12 month high of $2.35. The stock has a market capitalization of $16.59 million, a price-to-earnings ratio of -1.78 and a beta of 0.23.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. On average, research analysts anticipate that Allarity Therapeutics will post -78.08 earnings per share for the current year.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.